Celgene (NASDAQ:CELG) announced good news today about its blockbuster drug Revlimid. Did the stock jump as a result? Nope. Shares actually fell by more than 4%. Here's what happened.
The U.S. Food and Drug Administration approved Revlimid as a treatment for patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included Velcade, a drug marketed by Johnson & Johnson and Takeda. Revlimid was previously approved in the U.S. as a second-line treatment for multiple myeloma and for treating myelodisplastic syndromes.
Mantle cell lymphoma is a type of non-Hodgkin's lymphoma that is very rare, affecting only around 15,000 patients in the United States. Although a few treatments for the disease are available, Dr. Andre Goy with the Hackensack University Medical Center says that "there remains a tremendous unmet need" for patients who have not responded satisfactorily after previous treatments. FDA approval for Revlimid makes it the first oral therapy for mantle cell lymphoma.
... but old news?
You might think that approval of a new indication would cause some excitement for investors. So why did Celgene's shares fall?
One reason is that the market most likely already baked this approval into the price of the stock. Celgene announced solid results from its phase 2 study of Revlimid in treating mantle cell lymphoma in late 2012. In February, the FDA granted priority review for the supplemental New Drug Application. Most investors fully expected the approval to come through.
The FDA announcement also came soon after Celgene announced some disappointing news related to Revlimid. The biotech presented results earlier this week at the American Society of Clinical Oncology, or ASCO, annual meeting from a phase 3 study of a Revlimid combined with melphalan and prednisone in treating newly diagnosed multiple myeloma. Unfortunately for Celgene, patients on the Revlmid combo had median progression-free survival and overall survival rates that were lower than patients taking a high-dose chemotherapy and a tandem autologous stem cell transplant regimen.
Then there's the bigger picture. After a nice run in 2013, the markets seem to be taking a breather this week. Biotech stocks got hit even harder than the major indexes. Celgene is down 9% so far this week, but the iShares Nasdaq Biotechnology ETF isn't too far behind. The biotech ETF is down more than 5% for the week.
I think investors should take a long-term view with Celgene (and any other stock, for that matter.) Revlimid's juggernaut appears likely to keep on rolling. Even though J&J and Takeda have been on the market longer with Velcade, Revlimid is still the top dog for treating multiple myeloma.
Onyx Pharmaceuticals (UNKNOWN:ONXX.DL) is staking its claim to the multiple myeloma market with Kyprolis, but so far the rival drug is approved only as a third-line treatment. Kyprolis is really more of a direct competitor to Pomalyst, although I continue to believe that there's plenty of room for both drugs to succeed.
AbbVie (NYSE:ABBV) and Bristol-Myers Squibb (NYSE:BMY) joined forces on development of blood cancer drug elotuzumab. However, the partners are only in phase 3 trials. And two of those studies actually include use of elotuzumab along with Revlimid.
Revlimid still makes up around two-thirds of Celgene's revenue, but the company has several other up-and-comers. Abraxane, Apremilast, and Pomalyst appear to have plenty of potential. Vidaza is still showing firepower as well.
The latest FDA approval for Revlimid is just another cog in the wheel for Celgene. My view remains that the stock is a good long-term pick. With the recent pullback, investors with an eye toward the future could do well by scooping up some shares of this biotech.
Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.